Breast Cancer (BC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Breast cancer ranks as the second leading cause of cancer-related deaths among women worldwide. Approximately 1 in 8 women globally face a lifetime risk of developing breast cancer. The immunohistochemical classification of breast cancer, based on the expression of hormone receptors—estrogen (ER), progesterone (PR), and human epidermal growth factor (HER2)—is the most widely accepted. This classification delineates four primary subtypes: luminal A, luminal B, HER2-positive, and triple-negative. The pathogenesis of breast cancer involves a complex, multi-step process encompassing various cell types, making its prevention a formidable challenge globally. Early diagnosis remains a pivotal strategy for mitigating the disease's impact. In several developed nations, early detection efforts have elevated the 5-year relative survival rate of breast cancer patients to over 80%. The manifestation of breast cancer symptoms varies among individuals, and some women may remain asymptomatic until a routine mammogram detects the disease. Notable warning signs include a new lump in the breast or underarm, thickening or swelling of part of the breast, irritation or dimpling of the breast skin, redness or flaky skin in the nipple area, nipple retraction or pain, non-lactational nipple discharge including blood, changes in breast size or shape, and localized breast pain.
Multiple risk factors contribute to breast cancer, some immutable and others modifiable through lifestyle changes. These risk factors include:
- Gender: Women are at a higher risk than men.
- Age: Risk increases with age, with most cases occurring post-50.
- Family History: A close relative with breast cancer elevates risk.
- Genetics: Inherited mutations like BRCA1 and BRCA2 increase susceptibility.
- Menstrual History: Early menarche (before age 12) or late menopause (after age 55) slightly raises risk.
- Weight: Overweight and obesity are risk factors; maintaining a healthy weight is protective.
- Lifestyle: Alcohol consumption, smoking, and highly processed foods elevate risk. Limiting alcohol and processed foods is advisable.
- Environmental Factors: Exposure to chemicals in water, food preparation, and high air pollution levels may increase risk.
Current therapeutic strategies for breast cancer include five primary options: surgery, radiation, hormone therapy, chemotherapy, and targeted therapies. Most treatment regimens incorporate a combination of these modalities. Early-stage breast cancer patients often qualify for breast-conserving surgery with radiotherapy or mastectomy, with no significant difference in survival or local recurrence rates between these approaches. Sentinel node biopsy is utilized for axillary staging, reducing the necessity for extensive axillary dissection in sentinel node-positive patients. Adjuvant systemic therapy is widely employed, with molecular profiling facilitating personalized treatment for hormone receptor-positive cancers.
Despite significant advancements, challenges remain in managing early-stage breast cancer. These include addressing the variability in clinical outcomes associated with tumor heterogeneity, particularly within ER-positive subtypes; improving treatments for subsets unresponsive to existing therapies; and developing biomarkers to predict therapeutic response or necessity for ongoing treatment. Furthermore, enhancing the patient experience by minimizing unnecessary therapy and improving supportive care to reduce treatment-related side effects and socioeconomic disruptions is crucial.
The broad opportunity areas in Breast Cancer (BC) include,
Closing statement: Targeting these opportunities would help drug marketers capture substantial patient share in Breast Cancer (BC) and achieve commercial success.
Thelansis report on Breast Cancer (BC) provides in-depth insights into the disease and patient segments, along with the areas of unmet need and drug development pipeline. The report answers key questions such as,
KOL Perspectives:
“The most significant unmet medical need lies within the realm of triple-negative breast cancer (TNBC), a disease that continues to carry a substantial risk of systemic relapse and eventual mortality due to metastatic spread. For patients with early-stage TNBC, intensified adjuvant chemotherapy proves beneficial, and the incorporation of an anthracycline, a taxane, and an alkylating agent aligns with clinical trial evidence in TNBC, provided it is feasible."— USA – Based – Oncologist.
“Despite the significant impact of breast cancer in older patients, challenges related to diagnosing and treating the elderly remain complex due to the scarcity of clinical trials specifically focused on this patient population.”— Japan – Based - Oncologist.
About Thelansis
Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area, including both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ bio-pharma reports covering epidemiology studies and market forecasting, as well as opportunity assessment based on the KOL interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team with a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Offerings in the orphan indications: Syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.
The developers and marketers of drugs in orphan indications can engage Thelansis for customized market research. They can gain possible solutions for ensuring considerable market penetration for their respective therapies.
?For more information, please contact:
Ankit Sahoo
Email- [email protected]
Contact No: +91- 6397-349664